Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category
Nuvau Announces Voting Results of Its Annual and Special Meeting of Shareholders and Announces the Appointment of Steven Bowles as Chair of the Board
SAGA Metals Appoints Accomplished Mining Executive Peter Hogendoorn to Board of Advisors and Engages Xander Capital Partners
Blue Lagoon Announces Major Steps Toward Production: Fully Funded, Government Inspections Passed, and Water Treatment Plant Completed
